-
GKB Ophthalmics Announces Positive Results from Phase 2b Study of GKB120 in Wet AMD
GKB Ophthalmics Ltd. (GKB), a clinical-stage biopharmaceutical company focused on developing innovative therapies for the treatment of ophthalmic diseases, today announced positive topline results from its Phase 2b clinical study evaluating the efficacy and safety of GKB120 for the treatment of wet age-related macular degeneration (wet AMD).
-
GKB Ophthalmics to Present at the 41st Annual J.P. Morgan Healthcare Conference
GKB Ophthalmics Ltd. (GKB), a clinical-stage biopharmaceutical company focused on developing innovative therapies for the treatment of ophthalmic diseases, today announced that it will present at the 41st Annual J.P. Morgan Healthcare Conference. The conference will be held in San Francisco, California from January 9-12, 2023.
-
GKB Ophthalmics Announces Initiation of Phase 2 Clinical Trial of GKB120 for the Treatment of Diabetic Macular Edema
GKB Ophthalmics Ltd. (GKB), a clinical-stage biopharmaceutical company focused on developing innovative therapies for the treatment of ophthalmic diseases, today announced the initiation of a Phase 2 clinical trial to evaluate the efficacy and safety of GKB120 for the treatment of diabetic macular edema (DME).
-
GKB Ophthalmics Announces Positive Results for Phase 2b Trial of Novel Glaucoma Treatment
GKB Ophthalmics Ltd. (GKB), a clinical-stage biopharmaceutical company developing innovative therapies for glaucoma and other eye diseases, today announced positive topline results from its Phase 2b clinical trial evaluating its novel glaucoma treatment, GKB101. The trial met its primary endpoint, demonstrating a statistically significant reduction in intraocular pressure (IOP) compared to placebo at all three timepoints evaluated (day 8, month 3, and month 6).
-
GKB Ophthalmics Raises $50 Million in Series C Financing to Advance Glaucoma Pipeline
GKB Ophthalmics Ltd. (GKB), a clinical-stage biopharmaceutical company focused on developing innovative therapies for glaucoma, today announced the closing of a $50 million Series C financing. The financing was led by new investor OrbiMed and included participation from existing investors Advent Life Sciences, Arix Bioscience, and Ysios Capital.
-
GKB Ophthalmics Announces Initiation of Phase 2b Trial of Novel Glaucoma Treatment
GKB Ophthalmics Ltd. (GKB), a clinical-stage biopharmaceutical company focused on developing innovative therapies for glaucoma, today announced the initiation of a Phase 2b clinical trial evaluating its novel glaucoma treatment, GKB101. The trial is designed to evaluate the safety and efficacy of GKB101 in patients with glaucoma.
-
GKB Ophthalmics Partners with Ocular Therapeutix to Distribute Beovu® in the UK and Ireland
GKB Ophthalmics Ltd., a leading ophthalmic pharmaceutical company, today announced a partnership with Ocular Therapeutix, Inc. (NASDAQ: OCUL) to exclusively distribute Beovu® (brolucizumab) in the UK and Ireland. Beovu® is a groundbreaking treatment for neovascular (wet) age-related macular degeneration (nAMD).
-
GKB Ophthalmics Announces FDA Approval of XIPERE™ (triamcinolone acetonide injectable suspension) for the Treatment of Diabetic Macular Edema
GKB Ophthalmics today announced that the U.S. Food and Drug Administration (FDA) has approved XIPERE™ (triamcinolone acetonide injectable suspension) for the treatment of diabetic macular edema (DME). DME is a leading cause of vision loss in people with diabetes.
-
GKB Ophthalmics Announces Positive Phase 3 Results for GKB1205 in Wet Age-Related Macular Degeneration
GKB Ophthalmics today announced positive topline results from the Phase 3 clinical trial evaluating the efficacy and safety of GKB1205 for the treatment of wet age-related macular degeneration (AMD). The trial met its primary endpoint, demonstrating that GKB1205 was superior to aflibercept in improving vision at week 48.
-
GKB Ophthalmics Receives FDA 510(k) Clearance for Intraoperative Mitomycin-C Delivery Device
The device is designed to deliver mitomycin-C, a chemotherapy drug, directly to the surgical site during glaucoma surgery.
-
GKB Ophthalmics Announces Positive Topline Results from Phase 2b Trial of GKB101 for the Treatment of Dry Eye Disease
The trial met its primary endpoint, demonstrating a statistically significant improvement in symptoms of dry eye disease.
-
GKB Ophthalmics Raises $30 Million in Series C Financing
The financing will be used to advance the development of GKB Ophthalmics' pipeline of ophthalmic drugs and devices.
-
GKB Ophthalmics Announces Positive Results from Phase 2b Clinical Trial of GKB121 in Patients with Wet Age-Related Macular Degeneration (AMD)
GKB Ophthalmics Ltd. (AIM: GKB), a leading ophthalmic pharmaceutical company, today announced positive topline results from the Phase 2b clinical trial of GKB121, its investigational treatment for wet age-related macular degeneration (AMD).
-
GKB Ophthalmics Announces Strategic Partnership with Novartis to Develop and Commercialize GKB121 for Wet Age-Related Macular Degeneration (AMD)
GKB Ophthalmics Ltd. (AIM: GKB), a leading ophthalmic pharmaceutical company, today announced a strategic partnership with Novartis (NYSE: NVS) to develop and commercialize GKB121, its investigational treatment for wet age-related macular degeneration (AMD).
-
GKB Ophthalmics Announces Initiation of Phase 2a Clinical Trial of GKB121 in Patients with Diabetic Macular Edema (DME)
GKB Ophthalmics Ltd. (AIM: GKB), a leading ophthalmic pharmaceutical company, today announced the initiation of a Phase 2a clinical trial of GKB121, its investigational treatment for diabetic macular edema (DME).